| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1887 | |
| Phytochemical name or plant extracts | 3,4-bis-3,4,5-trimethoxybenzylidene-dihydrofuran (BTMB) | |
| PMID | 27956520 | |
| Literature evidence | BTMB was shown to significantly suppress the growth of mammary carcinoma and therefore to have potential as an anticancer therapeutic agent. | |
| IUPAC name | (3E,4E)-3-[(3,4,5-trimethoxycyclohexyl)methylidene]-4-[(3,4,5-trimethoxyphenyl)methylidene]oxolan-2-one | |
| Phytochemicals’ class or type of plant extracts | Lignin | |
| Source of phytochemicals or plant Extracts | Taiwania cryptomerioides | |
| Geographical availability | China South-Central, Myanmar, Taiwan, Tibet, Vietnam | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | CDC2, Cyclin D1, Cyclin E | |
| Gene or Protein evidence | BTMB inhibited cell proliferation and induced cell apoptosis through the suppression of cell-cycle regulatory proteins such as cdc2, cyclin D1, and cyclin E and augmented the expression of apoptotic proteins such as c-caspase-3 and c-PARP proteins. | |
| Target pathways | it is shown that BTMB was able to produce therapeutic effects through the dual inhibition of the PI3K/Akt/mTOR and MEK/ERK signaling pathways in human TNBC MDA-MB-468 cells. | |
| IC50 | 2.6 μmol/L against MDA-MB-468 | |
| Potency | BTMB was shown to significantly suppress the growth of mammary carcinoma and therefore to have potential as an anticancer therapeutic agent. | |
| Cell line/ mice model | MDA-MB-468 | |
| Additional information | BTMB treatment significantly inhibited the growth of mammary carcinoma in a mouse xenograft model and that this inhibition is due, in part, to the suppression of the cyclin D1 proteins in these tumor-bearing animals. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:263753-1 | |
| Safety | NA |